Abbott Russia

Assets

As of April 2018, more than 3,000 employees work in Abbott's office in Moscow, as well as in a branch in St. Petersburg and throughout Russia and at Veropharm enterprises in Volginsky (Vladimir Region), Belgorod and Voronezh.

History

2021: Opening of the Research and Technical Production Center based on Veropharm

On October 19, 2021, Abbott announced the opening of the Scientific and Technical Production Center on the basis of the Veropharm production site (Abbott group) in Belgorod. More details here.

2018

Opening of full-cycle didrogesterone production in Belgorod

On April 10, 2018, Abbott announced the opening of a full-cycle production line at the Veropharm plant (part of the Abbott group) in Belgorod. The purpose of the launch, as explained in the company, is to localize the production of the drug Abbott to maintain female reproductive health, which meets the strategic tasks of the state to increase the birth rate in Russia. More details here.

Media Service Contract with Starlink

At the beginning of 2018, according to the results of the tender, Abbott Laboratories extended the contract with Starlink (Publicis Media) for the full media service of the Similac, Maloezhka, Irs19, Imudon, Dufalak, Duspatalin, Dufamishki, and Creamer brands.

2016: Drop in revenue in Russia by 10% to $483 million

In June 2016, Abbott Laboratories published an annual financial report according to which developed and fast-growing markets divide Abbott's revenue by 50%. The latter include Russia, where sales of the company decreased in the financial year to $483 million from $536 million a year earlier (a decline of 10%). Throughout the company's product line, sales in Russia account for about 2.4%. At the same time, the Russian market occupies 10% of the manufacturer's revenue from sales of medicines in the so-called fast-growing markets. Latin America (32%) and India (21%) generate more income.

By the end of June 2016, the division in Russia employs 3.5 thousand people. At this time, Abbott records an increase in the number of laboratory optimization projects in Russia. Managing Director of the Diagnostic Division of Abbott in Russia and the CIS Dmitry Paramonov:

"In 2012-2013, Abbott took part in only a few projects to optimize laboratories in Russia, today we have more than a dozen such projects. For example, projects to centralize laboratories in Oktyabrsky and Birsk (Bashkiria), where we took part, were successfully completed. "

2014: Elena Kartasheva - CEO

On July 1, 2014, it was announced that Leonid Parshenkov, who served as the general director of Abbott in Russia, was appointed regional director for African countries of the division of Abbott drugs recognized on the market.

As head of Abbott in Russia, Leonid Parshenkova was replaced by Elena Kartasheva.

2010: Leonid Parshenkov appointed CEO

After the acquisition of Solvey-Pharma by Abbott, Leonid Parshenkov took over as CEO of Abbott in Russia.

1970s: First deliveries to the USSR

Abbott began deliveries to the USSR in the late 1970s.